Overview
Renal involvement in malignant disease is a multifaceted issue that significantly impacts patient outcomes, particularly in advanced stages of cancer. This condition often manifests through complications such as malignant ascites (MA), which accounts for approximately 10% of all ascites cases and frequently occurs in the terminal phases of gastrointestinal and ovarian cancers [PMID:37080735]. The management of these complications not only affects quality of life but also influences healthcare costs, with substantial expenditures concentrated in the end-of-life period [PMID:39731088]. Hospitals play a pivotal role in caring for patients with advanced malignancies, with nearly half of cancer deaths occurring in acute-care settings [PMID:30853797]. Effective integration of palliative care early in the disease trajectory is crucial for improving both the quality of life and potentially extending survival, as evidenced by studies showing benefits in lung cancer patients [PMID:40044975]. However, late referrals to palliative care remain a common issue, with median referrals occurring only months before death, often too late to maximize benefits [PMID:40044975].
Epidemiology
The epidemiology of renal involvement in malignant disease underscores the significant burden on healthcare systems and patients alike. Advanced cancer patients frequently experience complications that strain both their physical health and financial resources. For instance, malignant ascites (MA) is a notable complication, affecting about 10% of ascites cases and commonly seen in advanced gastrointestinal and ovarian cancers [PMID:37080735]. These patients often face substantial symptom burden, which can be exacerbated by the high costs associated with end-of-life care. Studies indicate that nearly half of cancer deaths occur in acute-care settings, highlighting the critical role hospitals play in managing these complex cases [PMID:30853797]. Additionally, demographic data from a retrospective analysis of 624 patients reveal a median age of 58 years, with a slight male predominance (59.3%) [PMID:25412940]. Metastatic patterns often involve the liver (34.8%), bone (31.5%), lung (23.3%), and brain (16.9%), reflecting the systemic nature of advanced malignancies [PMID:25412940]. These patterns underscore the need for comprehensive multidisciplinary care approaches to address the diverse clinical presentations and complications.
Clinical Presentation
The clinical presentation of renal involvement in malignant disease is marked by a significant symptom burden that can profoundly affect patients' quality of life and decision-making processes. Early stages of cancer can already present challenging symptoms, emphasizing the importance of concurrent palliative care to alleviate distress [PMID:40044975]. Malignant ascites, characterized by abdominal swelling, pain, nausea, anorexia, vomiting, and dyspnea, exemplifies the multifaceted nature of these symptoms [PMID:37080735]. Among patients considering medically assisted dying (MAID), physical suffering is a predominant factor, cited by 77.4% as the primary reason [PMID:33208428]. Anorexia and cachexia are common in the dying process, often rendering nutritional support via central parenteral nutrition (CANH) ineffective due to impaired nutrient utilization [PMID:32129139]. Biomarkers such as elevated C-reactive protein (CRP) levels and low albumin levels at admission are associated with poorer outcomes, indicating systemic inflammation and malnutrition [PMID:32118773]. Psychological factors, including unrealistic hope for therapeutic benefit, can complicate end-of-life planning and decision-making, necessitating careful communication strategies to align care with patient values and preferences [PMID:31783851]. Comprehensive symptom assessment tools, such as the Edmonton Symptom Assessment Scale, are crucial but often underutilized, with only 23.8% of MAID-requesting patients having completed such assessments [PMID:33208428].
Diagnosis
Diagnosing renal involvement in malignant disease often relies on a combination of clinical symptoms, laboratory findings, and imaging studies. Elevated CRP levels and low albumin levels serve as important prognostic indicators, with the CRP/albumin ratio emerging as a valuable tool for predicting short-term survival outcomes within 30 days in terminal cancer patients [PMID:32118773]. However, predicting life expectancy and the response to aggressive interventions like nutritional support remains challenging due to the complex interplay of disease progression and patient-specific factors [PMID:8798219]. Imaging modalities such as ultrasound, CT scans, and MRI can help identify metastatic spread and organ dysfunction, particularly in the liver, bone, lung, and brain, which are common sites of metastasis [PMID:25412940]. Despite these diagnostic tools, the clinical utility of these biomarkers and imaging findings must be interpreted cautiously, considering the variability in patient responses and the need for individualized care plans. The complexity in clinical decision-making underscores the importance of integrating palliative care early to manage symptoms effectively and align care with patient preferences [PMID:16475428].
Differential Diagnosis
Differentiating renal involvement in malignant disease from other causes of symptoms such as anorexia, dehydration, and respiratory distress is crucial for appropriate management. Loss of appetite and reduced oral intake can often stem from reversible causes like pain, anxiety, depression, and medication side effects, which should be addressed before considering more invasive interventions such as central parenteral nutrition (CANH) [PMID:32129139]. While respiratory symptoms like secretion and confusion may correlate with parenteral hydration in bivariate analyses, breathlessness remains a significant and independent predictor of such interventions in adjusted models [PMID:38342476]. Distinguishing between physiological dehydration typical in end-of-life processes and clinically problematic dehydration is essential for tailoring fluid management strategies. Clinicians must consider both medical indications and patient-centered preferences to avoid unnecessary interventions that may not improve quality of life and could introduce risks such as infections and fluid overload [PMID:18026063]. Comprehensive symptom evaluation and patient-specific assessments are vital to ensure that interventions are evidence-based and aligned with patient goals.
Management
The management of renal involvement in malignant disease requires a multifaceted approach that integrates palliative care principles to optimize symptom control and quality of life. Early integration of palliative care has been shown to improve quality of life, reduce depressive symptoms, and even prolong survival in patients with lung cancer [PMID:40044975]. Strategies such as Goals of Care Programs and Trigger Tools facilitate timely palliative care referrals, enhancing overall patient outcomes [PMID:40044975]. In Japan, common palliative interventions include reduced hydration, paracentesis, and analgesic therapy, although the evidence base supporting these practices is still evolving [PMID:37080735]. Central parenteral nutrition (CANH) is frequently debated due to its limited efficacy and potential risks, including infections and aspiration, particularly in the context of end-of-life care [PMID:32129139]. Monitoring biomarkers like CRP and albumin can aid in prognosticating and adjusting care plans to better align with patient expectations and clinical realities [PMID:32118773]. Effective communication strategies that emphasize patient values and preferences, alongside providing accurate information about clinical options, are crucial for informed decision-making and reducing decisional conflict [PMID:31783851]. Pharmacists play a vital role in managing complex medication regimens, particularly opioids, which are prevalent in palliative care settings [PMID:31783834]. Despite these advancements, late referrals to palliative care remain a challenge, with many patients identified as palliative less than two months before death, limiting the effectiveness of supportive interventions [PMID:30853797].
Complications
The management of renal involvement in malignant disease often encounters several complications that can significantly impact patient comfort and survival. Central parenteral nutrition (CANH) is frequently associated with adverse effects such as fluid overload, which can exacerbate cardiac failure and respiratory distress, as well as increase the risk of infections and hospital admissions [PMID:32129139]. In patients nearing the end of life, worsening symptoms like anorexia, cachexia, and functional decline necessitate additional support, such as hospice care, to manage symptom burdens effectively [PMID:37524007]. Adverse effects leading to the discontinuation of CANH include localized and generalized edema, respiratory secretions, and gastrointestinal symptoms like nausea and vomiting [PMID:29343167]. Dehydration, while sometimes necessary for symptom management, must be carefully monitored to avoid causing significant distress or discomfort, as highlighted by studies emphasizing the need for purposeful fluid management [PMID:16475428]. Clinicians must remain vigilant for these complications, balancing the need for symptom relief with the potential risks of aggressive interventions.
Prognosis & Follow-up
Prognosis in patients with renal involvement due to malignant disease is often guarded, with significant variability based on factors such as metastatic burden and systemic markers. The median survival time following the diagnosis of malignant ascites ranges from 1 to 4 months, reflecting its association with advanced disease stages [PMID:37080735]. Poor prognostic indicators include liver metastasis, low serum albumin levels, and the presence of edema [PMID:37080735]. Biomarker assessments, such as the CRP/albumin ratio, consistently predict worse survival outcomes in terminal cancer patients, independent of cancer type and stage [PMID:32118773]. Late referrals to palliative care, with median referrals occurring just 17.2 days before death, often limit the effectiveness of supportive interventions [PMID:40044975]. Hospice care can significantly enhance quality of life in the terminal phase, particularly for patients undergoing conservative kidney management (CKM), by providing multidisciplinary expertise in symptom management [PMID:37524007]. Continuous monitoring and timely reassessment of patient status are essential to adjust care plans and manage expectations effectively, ensuring that interventions align with both clinical outcomes and patient preferences.
Special Populations
Special populations, including older adults, nonwhite ethnicities, and those with limited English proficiency, face unique challenges in managing renal involvement due to malignant disease. Recruitment processes for palliative care advisory roles often fail to adequately include these groups, necessitating adaptations to ensure inclusivity [PMID:37625026]. Patients with chronic kidney disease (CKD) present specific barriers to hospice care delivery, requiring tailored strategies to overcome logistical and clinical hurdles [PMID:37524007]. Pharmacists, while increasingly involved in palliative care, often cite insufficient time and staffing as barriers to their full engagement, highlighting gaps in multidisciplinary care coordination [PMID:24018207]. Caregiver perspectives emphasize the importance of discovering patient preferences, providing clear information, and addressing concerns related to interventions like artificial hydration, underscoring the need for empathetic and patient-centered communication [PMID:9447808]. Tailoring interventions and support systems to meet the diverse needs of these populations is crucial for optimizing outcomes and enhancing the overall quality of end-of-life care.
Key Recommendations
References
1 Bucklar N, Schettle M, Feuz M, Däster F, Christ SM, Blum D et al.. Early integration or last consultation: in-house palliative care involvement for hospitalized patients in tertiary medicine-a retrospective analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025. link 2 Tolppanen AM, Lamminmäki A, Kataja V, Tyynelä-Korhonen K. Specialized palliative outpatient clinic care involvement associated with decreased end-of-life hospital costs in cancer patients, a single center study. BMC palliative care 2024. link 3 Kadono T, Ishiki H, Yokomichi N, Ito T, Maeda I, Hatano Y et al.. Malignancy-related ascites in palliative care units: prognostic factor analysis. BMJ supportive & palliative care 2024. link 4 Vlckova K, Polakova K, Tuckova A, Houska A, Loucka M. Views of patients with advanced disease and their relatives on participation in palliative care research. BMC palliative care 2021. link 5 Munro C, Romanova A, Webber C, Kekewich M, Richard R, Tanuseputro P. Involvement of palliative care in patients requesting medical assistance in dying. Canadian family physician Medecin de famille canadien 2020. link 6 Carter AN. To What Extent Does Clinically Assisted Nutrition and Hydration Have a Role in the Care of Dying People?. Journal of palliative care 2020. link 7 Ju SY, Ma SJ. High C-reactive protein to albumin ratio and the short-term survival prognosis within 30 days in terminal cancer patients receiving palliative care in a hospital setting: A retrospective analysis. Medicine 2020. link 8 van Lent LGG, Stoel NK, van Weert JCM, van Gurp J, de Jonge MJA, Lolkema MP et al.. Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT). BMC palliative care 2019. link 9 Adisa R, Anifowose AT. Pharmacists' knowledge, attitude and involvement in palliative care in selected tertiary hospitals in southwestern Nigeria. BMC palliative care 2019. link 10 Tung J, Chadder J, Dudgeon D, Louzado C, Niu J, Rahal R et al.. Palliative care for cancer patients near end of life in acute-care hospitals across Canada: a look at the inpatient palliative care code. Current oncology (Toronto, Ont.) 2019. link 11 Caspers AM, Eichenauer DA, Pralong A, Simon ST. Hospital Palliative Care Team Involvement in Inpatients with Hematologic Malignancies: A Retrospective Study. Journal of palliative medicine 2025. link 12 Martinsson L, Strang P, Lundström S, Hedman C. Parenteral Hydration in Dying Patients With Cancer: A National Registry Study. Journal of pain and symptom management 2024. link 13 Ohinata H, Aoyama M, Hiratsuka Y, Mori M, Kikuchi A, Tsukuura H et al.. Symptoms, performance status and phase of illness in advanced cancer: multicentre cross-sectional study of palliative care unit admissions. BMJ supportive & palliative care 2024. link 14 Mendoza K, Killeen K, Lakin JR, Leiter RE, Sciacca KR, Gelfand SL. Adding Pals to KidneyPal: Creating a Virtual Patient and Family Advisory Council for Kidney Palliative Care. Journal of palliative medicine 2023. link 15 Bursic AE, Schell JO. Hospice Care in Conservative Kidney Management. Seminars in nephrology 2023. link 16 Louie AD, Miner TJ. Palliative surgery and the surgeon's role in the palliative care team: a review. Annals of palliative medicine 2022. link 17 Dhollander N, Deliens L, Van Belle S, De Vleminck A, Pardon K. Differences between early and late involvement of palliative home care in oncology care: A focus group study with palliative home care teams. Palliative medicine 2018. link 18 Davies AN, Waghorn M, Webber K, Johnsen S, Mendis J, Boyle J. A cluster randomised feasibility trial of clinically assisted hydration in cancer patients in the last days of life. Palliative medicine 2018. link 19 Türker İ, Kömürcü Ş, Arıcan A, Doruk H, Özyılkan Ö, Coşkun HŞ et al.. Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study. Medical oncology (Northwood, London, England) 2014. link 20 Ise Y, Morita T, Katayama S, Kizawa Y. The activity of palliative care team pharmacists in designated cancer hospitals: a nationwide survey in Japan. Journal of pain and symptom management 2014. link 21 White CD, Hardy JR, Gilshenan KS, Charles MA, Pinkerton CR. Randomised controlled trials of palliative care - a survey of the views of advanced cancer patients and their relatives. European journal of cancer (Oxford, England : 1990) 2008. link 22 Bavin L. Artificial rehydration in the last days of life: is it beneficial?. International journal of palliative nursing 2007. link 23 Maxwell LA. Purposful dehydration in a terminally ill cancer patient. British journal of nursing (Mark Allen Publishing) 2005. link 24 Ling J, Rees E, Hardy J. What influences participation in clinical trials in palliative care in a cancer centre?. European journal of cancer (Oxford, England : 1990) 2000. link00330-5) 25 Parkash R, Burge F. The family's perspective on issues of hydration in terminal care. Journal of palliative care 1997. link 26 Bozzetti F, Amadori D, Bruera E, Cozzaglio L, Corli O, Filiberti A et al.. Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care. Nutrition (Burbank, Los Angeles County, Calif.) 1996. link91120-x) 27 Sutcliffe J, Holmes S. Dehydration: burden or benefit to the dying patient?. Journal of advanced nursing 1994. link
27 papers cited of 43 indexed.